Court reverses Risperdal decision

Share this article:

The Arkansas Supreme Court has put $1.2 billion into Johnson & Johnson's accounts.

The court ruled last week that a previous ruling, which slapped the drugmaker for violating Medicaid fraud and deceptive marketing practices, was erroneous because the wrong standard was used.

As explained by Reuters, the court reversed the financial penalty because the court said plaintiffs invoked a law that applies to healthcare facilities, as opposed to a corporation.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.